



25 March 2020

Update on COVID-19 Impact

Melbourne, Australia, 25 March 2020; dorsaVi (ASX: DVL) would like to inform the market on the current status of its business given the potential impacts of the COVID-19.

As a business, dorsaVi's primary focus is on ensuring the health and wellbeing of staff and supporting our customers through this period. We have taken steps to transition staff to a work from home arrangement and we continue to work closely with our customer base to support them in their business practices through this unprecedented time.

dorsaVi is also acutely aware of the need to protect cash reserves and ensure that the business is sustainable through this period.

dorsaVi currently has \$1.83 million cash at bank, however it is anticipated that there will be an impact to new sales as a result of COVID-19. To mitigate, actions have been taken to reduce costs and optimise cash.

All staff have agreed to reduce their working hours by (approximately) 30% commencing immediately. Operational expenses have been reduced by 20% with no travel and discretionary spend. The extent of the impact of COVID-19 on the Company's recurring revenue stream from existing clients is difficult to assess at this stage but will be closely monitored.

The business recognises the potential for COVID-19 to impact the business over a prolonged period. As the Company has further clarity it will make further announcements to the market.

We wish everyone well during these difficult times.

- ENDS -

For more information about dorsaVi or to arrange an interview, please contact:

Andrew Ronchi
CEO dorsaVi
+61 417 882 267
+1 858 333 9446
ar@dorsavi.com

Matt May
GM dorsaVi
+61 409 324 949
mmay@dorsavi.com

The release of this announcement was authorised by Andrew Ronchi, CEO.

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Occupational Health and Safety (OHS):** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions - ViMove, ViMove2 and Professional Suite – which provide objective assessment, monitoring outside the clinic and immediate biofeedback. dorsaVi is currently used by medical and physiotherapy practices globally.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used in the US by the National Basketball Association (NBA), the Major Soccer League (MLS) and the National Football League (NFL), by the AFL and NRL clubs and by Barclays Premier League (EPL) clubs, England and Wales Cricket Board and the Board of Control for Cricket in India as well as various Olympic teams and athletes internationally.

Further information is available at www.dorsavi.com